Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess in a post-approval clinical setting the
safety profile of sevelamer carbonate (Renvela®) tablets and powder in adult
hyperphosphataemic chronic kidney disease (CKD) patients not on dialysis with serum
phosphorus ≥1.78 mmol/L. Patients will be treated in accordance with the Renvela® Summary of
Product Characteristics (SmPC) and followed according to the investigator's standard clinical
practice management. Each patient will be followed up for 12 months or up to the time they
start dialysis, whichever occurs first.